Methods for detecting lung cancer

Spectroscopic analysis of oral cavity cells identifies lung disease through feature distributions, providing a less invasive and more reliable method for early lung cancer detection.

JP7596378B2Active Publication Date: 2024-12-09SIERRA MEDICAL LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022528543
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2019-11-15
Publication Date
2024-12-09
Estimated Expiration
2039-11-15

AI Technical Summary

Technical Problem

Current methods for detecting lung cancer are invasive, inconvenient, and lack early detection capabilities.

Method used

A diagnostic method using spectroscopic analysis of oral cavity cells to identify features of interest, determining feature distributions, and diagnosing lung disease based on asymmetric or spread distributions, with thresholds and ratios to enhance sensitivity and specificity.

Benefits of technology

Enables less invasive and more reliable early detection of lung cancer by analyzing cell spectra, achieving sensitivity and specificity in distinguishing between healthy and cancerous samples.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007596378000007
    Figure 0007596378000007
  • Figure 0007596378000008
    Figure 0007596378000008
  • Figure 0007596378000001
    Figure 0007596378000001
Patent Text Reader

Abstract

The present invention relates to a diagnostic method for determining lung disease, the method comprising the steps of obtaining a plurality of spectra produced by spectroscopic analysis of a plurality of cells, determining a feature of interest from each of the plurality of spectra, determining a distribution of the feature of interest, and diagnosing the lung disease according to the distribution of the feature of interest.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the detection of lung cancer. [Background technology]

[0002] Lung cancer can be detected, for example, by taking an X-ray (including a tomography) or a biopsy of lung tissue. Summary of the Invention [Problem to be solved by the invention]

[0003] It is an object of the present invention to enable lung cancer and other respiratory diseases to be detected more conveniently, less invasively, at an earlier stage and more reliably than other approaches. [Means for solving the problem]

[0004] In a first aspect, a diagnostic method for determining pulmonary disease is provided, the method comprising the steps of obtaining a plurality of spectra generated by spectroscopic analysis of a plurality of cells, determining a feature of interest from each spectrum of the plurality of spectra, determining a distribution of the features of interest, and diagnosing pulmonary disease in response to the distribution of the features of interest.

[0005] The distribution can provide a distinction that can be indicative of pulmonary disease and can allow for less invasive, more convenient and reliable early stage identification of pulmonary disease (or subjects at risk for pulmonary disease).

[0006] Lung disease may be diagnosed when the distribution is asymmetric, which may be indicative of a particular lung disease or risk of lung disease.

[0007] The method may further include determining a ratio of outliers to non-outliers in the distribution of the feature of interest and determining an asymmetry based on the ratio. Such a ratio may provide a measure of the distribution and may be selected to provide a target sensitivity and / or specificity.

[0008] The distribution may be asymmetric if the ratio of outliers to non-outliers exceeds a threshold. The threshold may be at least 0.05, preferably at least 0.1, preferably at least 0.15. The threshold may be selected to provide a target sensitivity and / or specificity.

[0009] The outlier may be determined according to a one-sided boundary, or alternatively a two-sided boundary. The one-sided or two-sided boundary may be determined according to the mean of the feature of interest and / or according to the standard deviation of the feature of interest. The boundaries may be selected to provide a target sensitivity and / or specificity.

[0010] The method may further comprise determining a measure of asymmetry of the distribution of the feature of interest and determining the asymmetry based on the measure of asymmetry, which may be skewness, Pearson's skewness and / or kurtosis.

[0011] Pulmonary disease may be diagnosed when the distribution has a spread above a threshold. A distribution with a high spread, whether symmetric or asymmetric, may be indicative of a particular pulmonary disease or risk of pulmonary disease.

[0012] The method may further comprise determining a ratio of outliers to non-outliers in the distribution of the feature of interest and determining a spread above a threshold based on said ratio. Such a ratio may provide a measure of spread and may be selected to provide a target sensitivity and / or specificity. The outliers are preferably determined according to a two-sided boundary. The two-sided boundary may be determined according to the mean of the feature of interest and / or according to the standard deviation of the feature of interest.

[0013] The method may further comprise determining a standard deviation as the measure of spread, and pulmonary disease is diagnosed if the standard deviation exceeds a threshold. Other measures of spread may be used, including the full width at half maximum of a histogram of the distribution, a range between upper and lower parts such as quartiles, deciles or percentiles, the mean absolute deviation or a combination of two or more measures of spread.

[0014] For convenience and minimal invasiveness, the cells may be derived from the upper respiratory tract. The cells are preferably oral cells.

[0015] The spectroscopic analysis may be one or more of infrared spectroscopy, Fourier transform infrared spectroscopy, benchtop spectroscopy and / or Raman spectroscopy. The spectrum is preferably an absorption spectrum or a derivative thereof.

[0016] Preferably, at least 20 spectra are obtained, each spectrum from a different cell, preferably at least 50 spectra are obtained, more preferably at least 75 spectra are obtained, each spectrum from a different cell, and even more preferably at least 100 spectra are obtained, each spectrum from a different cell.

[0017] The feature of interest may be a peak area within the spectroscopic band of interest, an average value within the spectroscopic band of interest, a normal arithmetic mean, a weighted arithmetic mean or centroid, a value at a wavenumber of interest and / or a wavenumber at which a spectroscopic maximum or minimum occurs within the spectroscopic band of interest.

[0018] The spectroscopic band or wavenumber of interest is 1150 cm -1 Region: 1140~1160cm -1 , 1080cm -1 Region: 1070~1090cm -1 , 1065cm -1 in the region of 1060-1070 cm -1 , 1050cm -1 in the region of 1060-1070 cm -1 It may be one or more of the following:

[0019] The feature of interest may be a combination of two or more of the features of interest as described above.

[0020] The pulmonary disease may be lung cancer or a non-cancerous respiratory disease, optionally chronic obstructive pulmonary disease.

[0021] Preferably, each spectroscopic analysis relates to a portion of a single cell, preferably a portion of a single cell including the nucleus, said portion optionally including the cytoplasm.

[0022] The method may further comprise the step of normalizing the spectrum to the amide II peak height and / or calculating the second derivative of said spectrum.

[0023] The method may further include one or more of the steps of obtaining a plurality of cells from the subject and performing a spectroscopic analysis of the plurality of cells.

[0024] In another aspect, there is provided a computer program comprising code means for carrying out a method as above.

[0025] In another aspect, there is provided a computer readable medium carrying a computer program as aforesaid.

[0026] In another aspect, there is provided a system comprising a computer capable of executing a computer program as above. The system may further comprise a spectrometer.

[0027] In another aspect, computer programs and computer program products are provided that perform any of the methods described herein and / or embody any of the device features described herein. In another aspect, a non-transitory computer readable medium is provided that stores a program that performs any of the methods described herein and / or embody any of the device features described herein. In another aspect, a computer program product is provided that includes software code that performs any of the methods described herein. Features implemented in hardware may typically be implemented in software and vice versa. Any references to software and hardware features in this specification should be interpreted accordingly.

[0028] The invention also provides a signal embodying a computer program performing any of the methods and / or embodying any of the apparatus features described herein, and a method for transmitting such a signal, and a computer product having an operating system supporting a computer program performing any of the methods and / or embodying any of the apparatus features described herein.

[0029] Any apparatus features described herein may also be provided as method features, and vice versa.

[0030] Any feature of one aspect of the invention may be applied to other aspects of the invention in any suitable combination. In particular, method aspects may be applied to apparatus aspects and vice versa. Furthermore, any, some and / or all features of an aspect may be applied to any, some and / or all features of any other aspect in any suitable combination.

[0031] It will also be understood that certain combinations of the various features described and defined in any aspect of the present invention may be implemented and / or provided and / or used independently.

[0032] As used herein, means-plus-function features may alternatively be expressed in terms of their corresponding structure, such as a suitably programmed processor and associated memory.

[0033] These and other aspects of the present invention will become apparent from the following exemplary embodiments described with reference to the following figures. [Brief description of the drawings]

[0034] [Figure 1] 1 is a plot of spectral peak areas from samples from multiple analytes. [Diagram 2] 1 is a plot of the ratio of outliers compared to non-outliers for each sample. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0035] A sample of buccal cells is collected from the subject and fixed, for example, in 4% formaldehyde or 10% neutral buffered formalin (NBF) for 20 min. The cell suspension is cytospun onto a substrate suitable for IR transmission, for example a 1 mm thick, 22 mm diameter calcium fluoride (CaF2) or zinc selenide (ZnSe) IR window. Other suitable protocols for cell preparation may be used, for example, cytospinning may be omitted, the cells may be allowed to settle, excess liquid may be evaporated, or the cells may be smeared directly onto the window.

[0036] The buccal cell sample is analyzed with a suitable FTIR instrument. In one example, the sample is analyzed with a benchtop FTIR spectrometer equipped with a conventional (globar) light source. Suitable examples include a Perkin Elmer Spotlight 200i FT-IR microscope coupled to a Frontier spectrometer controlled with Spectrum 10 software or a ThermoFischer Scientific, Nicolet iN10 Mx infrared imaging microscope controlled with OMIC Picta software. The benchtop FTIR spectrometer may be liquid nitrogen cooled and may have a mercury cadmium telluride (MCT) detector. Examples of suitable IR detectors include a liquid nitrogen cooled mercury cadmium telluride (MCT) single element detector or a 64x64 array of liquid nitrogen cooled FPA detectors. In one example, single point transmission measurements are recorded using a 15x15 pm aperture. A larger aperture may be selected to interrogate a larger portion of the cell. The aperture may be selected to cover substantially the entire cell. To minimize Mie scattering, it is advantageous to choose an aperture smaller than the diameter of a cell.

[0037] Single-point transmission measurements are performed on 100 individual non-apoptotic, intact cells per sample, randomly selected from a sample of buccal cells (e.g., manually or automatically with cell identification by automated image processing). Measurements collate a portion of a single cell focused on the nucleus, preferably a portion including the nucleus and part of the cytoplasm (in variants, this portion may include only the nucleus or only the cytoplasm). Data are collected at wavelengths between 4000 and 600 cm. -1 The system was recorded at room temperature in the region of 1800–1000 cm -1 The 16 interferograms are then scaled to 4 cm before Fourier transformation. -1 The absorption spectra are averaged with a resolution of 4 cm. -1The background spectrum is calculated using as a reference the interferograms (16 interferograms averaged at a resolution of 100 s). A background spectrum is recorded, for example, before the first cell measurement and then after every 15th cell measurement.

[0038] Other examples of benchtop "FTIR spectrometer systems" include a Bruker HYPERION 3000 FTIR microscope coupled to an INVENIO spectrometer and OPUS software, or a Shimadzu AIM-9000 microscope coupled to an IRTracer-100 spectrometer and AIMsolution software.

[0039] In a variant, a synchrotron light source is used rather than a benchtop FTIR spectrometer with a conventional (globar) light source as described above. In one example, the synchrotron light source is provided by Diamond Light Source (Harwell Science and Innovation Campus, Didcot) using FTIR microspectroscopy on beamline 22. In this example, FTIR data is recorded using a Bruker IFS 66s spectrometer, which is fitted with a KBr beam splitter and coupled to a Bruker Hyperion 3000 microscope with a suitable IR detector, in one example running OPUS 7.0. White light images are recorded using a 36x objective on the microscope.

[0040] Various alternatives for sample analysis to obtain FTIR data are possible, for example, a 30×30 μm aperture may be used, background readings may be taken every 5 minutes while measurements are being made, and 256 or more interferograms may be averaged, among many other alternatives known to those skilled in the art.

[0041] The absorption spectrum data may be preprocessed. The absorption spectrum data may be preprocessed to obtain an absorption spectrum, for example, from 1465 to 1575 cm -1The absorption spectrum data may be pre-processed to calculate second derivatives, for example using 13-point Savitzky-Golay smoothing to narrow broad peaks and correct for any baseline drift. Alternative procedures for normalizing the spectra and / or finding appropriate derivatives of the spectra may be used, as is well known in the art. Pre-processing may also include steps of water subtraction, water vapor subtraction and / or baseline correction, as is well known in the art.

[0042] 1200~900cm -1 Certain bands of interest in the region of 1140–1160 cm show particularly large differences between the normalized spectra of samples from cancer patients and samples from healthy subjects. Four example bands of interest are -1 , 1070~1090cm -1 , 1060~1070cm -1 and 1040~1060cm -1 Another example of a band of interest is the 1050 cm -1 Bandwidth in the region of 1065 cm -1 Bandwidth in the region of 1080 cm -1 and 1150 cm -1 Examples of the band include the band in the range of

[0043] The means and standard deviations between the cancer and healthy groups may be analyzed to determine bands of particularly significant differences.

[0044] For a band of interest, determine the peak areas of the individual spectra within the band. Define a line between the start and end points of the normalized second derivative spectrum within that band. Calculate the area between the line and the peak / trough of the normalized second derivative spectrum for the band of interest (called the peak area).

[0045] The peak areas of the spectra are analyzed to identify samples from cancer patients.

[0046] A chi-square test of the calculated peak areas of a measurement set from a sample (containing data from approximately 100 individual cell spectra from the same patient) is performed to determine whether the data is normally distributed. It is observed that many measurement sets have data that are not normally distributed in different subjects, such as subjects with lung cancer and subjects without lung cancer. A Wilcoxon rank sum analysis is performed to show that data from different patients have similar or dissimilar distributions. It is observed that many patients have data that are differently distributed.

[0047] It is observed that the distribution of peak areas from samples belonging to the control group (subjects not affected by lung cancer) is different from the distribution of peak areas from samples belonging to the cancer group (subjects affected by lung cancer). The spectra of a particular sample form a cluster with some outliers along with some spectra from a random selection of cells. For the control group, the clusters are usually narrower, the number of outliers is smaller and the distribution is relatively symmetrical, whereas for the cancer group, the clusters are more dispersed, the number of outliers is larger and the asymmetry is more pronounced. It is expected that in cancer patients, the spectral distribution shifts due to a change in the proportion of cells randomly selected from the sample.

[0048] Various measures of distribution can be used to distinguish between samples from subjects without lung cancer and those with lung cancer. For example, for a set of measurements from a sample (i.e., about 100 individual cell spectra from the same patient), the ratio of outliers compared to non-outliers with reference to a particular boundary can provide a suitable measure of distribution.

[0049] FIG. 1 shows the 1059-1073 cm readings for each cell from each sample across a large number of subjects (with and without lung cancer). -1FIG. 1 shows a plot of peak areas in bands of interest within a region of . The y-axis is a metric value representing the peak area when the mean value of each sample (i.e., a cluster of approximately 100 individual cell spectra) is calibrated to 0. The x-axis is the spectral index number. Spectral index numbers 1 through approximately 1475 are from samples from healthy subjects, while the remaining spectra (darker shaded) are from samples from subjects suffering from lung cancer. Spectra from the same sample (i.e., from the same patient) form a set with consecutive index numbers spanning approximately 100 index numbers.

[0050] Figure 1 shows a boundary 2 defined to distinguish outliers. The boundary 2 is selected to optimize discrimination and in the example shown in Figure 1 is at -0.2 peak area metric value units. In another example, the boundary is at -0.08.

[0051] FIG. 2 shows a plot of the proportion of outliers compared to non-outliers for each sample (i.e., a dataset from the same patient). The proportions relate to the data in FIG. 1 with boundary 2 shown in FIG. 1. The y-axis is the proportion and the x-axis is the patient index number. Patient index numbers 1-15 are from samples belonging to the healthy group, and the remaining patient index numbers (darker shaded) are from samples belonging to the cancer group.

[0052] Figure 2 shows the threshold value 4 defined to distinguish between the control and cancer groups. Threshold value 4 was chosen to optimize discrimination and is 0.057 in the example shown in Figure 2. In another example, the threshold value is 0.14.

[0053] The discrimination shown in the example correctly classifies 3 out of 4 cancer samples and 13 out of 15 healthy samples. A sensitivity of 75% and a specificity of 87% are observed. In another example, the classifier correctly identifies cancer patients with a sensitivity of 60% and a specificity of 77.8%, and in another example, with a sensitivity of 60% and a specificity of 66%.

[0054] It is known that smoking can be a confounding factor in the analysis of samples from the respiratory tract. However, it is observed that samples obtained from subjects who are smokers and do not have lung cancer show the same pattern as samples obtained from subjects who are not smokers and do not have lung cancer. The distinction between samples from subjects who have or do not have lung cancer is not affected by whether the subject is a smoker or not.

[0055] It is known that chronic obstructive pulmonary disease may be a confounding factor in the analysis of samples from respiratory pathway.However, it is observed that the samples obtained from subjects who do not suffer from cancer but suffer from non-cancerous respiratory disease (including chronic obstructive pulmonary disease) are different from the samples obtained from subjects who suffer from lung cancer.The samples obtained from subjects who suffer from non-cancerous respiratory disease may show a different distribution from the samples obtained from subjects who do not suffer from respiratory disease.

[0056] In the illustrated example, a sample of oral cells is collected and analyzed. The sample of oral cells may be collected by oral swabbing or mouthwash. In variations, samples are collected from one or more sites of the upper respiratory tract, including other mouth, teeth, tongue tissue (e.g., swab collection), sputum, saliva, throat, nose or nasal tissue (e.g., swab collection).

[0057] In the illustrated example, boundary 2 and threshold 4 are selected based on the data shown in Figures 1 and 2. To set the boundary and threshold, a 2D optimization may be performed in the algorithm, where the boundary and threshold can be selected depending on the trade-off between sensitivity and specificity, i.e., optimizing either sensitivity or specificity, or finding the best balance between sensitivity or specificity for a particular usage scenario (as pre-screening or as part of a battery of tests).

[0058] In the illustrated example, the boundaries are one-sided, where only outliers on one side of the cluster are considered, while in another alternative, the boundaries are two-sided, one on each side of the cluster, where outliers on both sides of the cluster are considered.

[0059] In the illustrated example, only the band of interest is considered for classification, however, in another alternative, two or more bands of interest are considered.

[0060] In the illustrated example, peak areas within a particular band of interest are determined and analyzed, however, various alternative measures can be used to quantify features of interest within a spectrum. Some examples include: The absorbance (or the derivative of the absorbance) at a particular wavenumber, the average of the absorbance (or the derivative of the absorbance) over a range of wavenumbers (band of interest), which may be a regular arithmetic average or a weighted arithmetic average; Peak position, i.e., the wavenumber at which the peak or trough absorbance (or the derivative of the absorbance) occurs within the band of interest; and The centroid of the absorbance (or the derivative of the absorbance) over a range of wavenumbers (the band of interest).

[0061] A combination of two or more measures that quantify the feature of interest in the spectrum may be used.

[0062] Other measures to quantify the distribution and thereby distinguish between control and cancer groups include, for example: Standard deviation σ:

number

number

number

number

number

number

[0063] In the illustrated example, infrared spectroscopy data is used, although alternatives include Raman spectroscopy or another type of spectroscopy.

[0064] Various other modifications will be apparent to those skilled in the art.

[0065] It will be understood that the invention has been described above purely by way of example and modifications of detail can be made within the scope of the invention.

[0066] Reference numerals appearing in the claims are by way of illustration only and shall have no limiting effect on the scope of the claims.

[0067] The term "comprising" as used in the present specification and claims preferably means "consisting at least in part of."

Claims

1. A method for producing a method for detecting a plurality of cells in a same subject, comprising: acquiring a plurality of spectra generated by spectroscopic analysis of a plurality of cells in the same subject; determining a feature of interest from each of the plurality of spectra, where the feature of interest is a peak area within a spectroscopic band of interest, an average value within the spectroscopic band of interest, a value at a wavenumber of interest, or a wavenumber at which a spectroscopic maximum or minimum occurs within the spectroscopic band of interest; determining a ratio of a number of outliers to a number of non-outliers in a statistical distribution of the feature of interest by the plurality of cells of the same subject; and using the ratio as an indicator of whether or not a subject is affected with lung cancer.

2. The method for analyzing cells described in claim 1, further comprising a step of determining asymmetry based on the ratio.

3. The method for analyzing cells according to claim 2 , wherein the distribution is asymmetric when the ratio exceeds a threshold value.

4. The method for analyzing cells according to claim 3 , wherein the threshold is at least 0.

05.

5. The method for analyzing cells according to any one of claims 2 to 4, wherein the outlier is determined according to a one-sided boundary.

6. The method for analyzing cells according to claim 5 , wherein the one-sided boundary is determined depending on the mean of the feature of interest and / or depending on the standard deviation of the feature of interest.

7. The method of claim 1 , further comprising: determining a measure of asymmetry of the distribution of the feature of interest; and determining the asymmetry based on the measure of asymmetry.

8. The method of claim 7 , wherein the measure of asymmetry is at least one of skewness, Pearson's skewness, and kurtosis.

9. The method for analyzing cells described in claim 1, further comprising a step of determining a spread exceeding a threshold based on the ratio.

10. The method for analyzing cells according to claim 9 , wherein the outliers are determined according to both side boundaries.

11. The method for analyzing cells according to claim 9 or 10, further comprising the step of determining a standard deviation as a measure of the spread.

12. The method for analyzing cells according to any one of claims 1 to 11, wherein the plurality of cells are derived from the upper respiratory tract.

13. The method for analyzing cells according to any one of claims 1 to 12, wherein the plurality of cells are oral cells.

14. The method for analyzing cells according to any one of claims 1 to 13, wherein the spectroscopic analysis is infrared spectroscopic analysis, Fourier transform infrared spectroscopic analysis, benchtop spectroscopic analysis, or Raman spectroscopic analysis.

15. The method for analyzing cells according to any one of claims 1 to 14, wherein at least 100 spectra are obtained, each spectrum being from a different cell.

16. The method for analyzing cells according to any one of claims 1 to 15, wherein the feature of interest is a peak area within a spectral band of interest.

17. The method for analyzing cells according to any one of claims 1 to 15, wherein the feature of interest is an average value within a spectral band of interest.

18. A method for analyzing cells according to any one of claims 1 to 15, wherein the feature of interest is a value at a wavenumber of interest.

19. A method for analyzing cells according to any one of claims 1 to 15, wherein the feature of interest is a wavenumber at which a spectroscopic maximum or minimum occurs within a spectroscopic band of interest.

20. The spectral band of interest or the wavenumber of interest is 1150 cm -1 region, 1140-1160 cm -1 , 1080cm -1 region, 1070-1090 cm -1 , 1065cm -1 in the region of 1060-1070 cm -1 , 1050cm -1 in the region of 1060-1070 cm -1 The method for analyzing cells according to any one of claims 16 to 19, wherein the method is one or more of the following:

21. A method for analyzing cells according to any one of claims 16 to 20, wherein the feature of interest is a combination of two or more of the features of interest in claims 16 to 20.

22. A method for analysing cells according to any one of claims 1 to 21, wherein each spectroscopic analysis relates to a part of a single cell, preferably a part of a single cell comprising a nucleus.

23. The method for analyzing a cell according to claim 22 , wherein the portion includes a cytoplasm.

24. The method for analyzing cells according to any one of claims 1 to 23, further comprising the step of normalizing the spectrum to the amide II peak height.

25. The method for analyzing cells according to any one of claims 1 to 24, further comprising the step of calculating a second derivative of the spectrum.

26. A method for analyzing cells described in any one of claims 1 to 25, further comprising a step of obtaining the multiple cells from the same subject and / or a step of performing the spectroscopic analysis of the multiple cells.

27. A computer program for causing a computer to execute each step of the cell analysis method according to any one of claims 1 to 25.

28. A computer-readable recording medium having the computer program according to claim 27 recorded thereon.

29. 28. An analysis system comprising a computer loaded with the computer program of claim 27.

30. 30. The analytical system of claim 29, further comprising a spectrometer.

Citation Information

Patent Citations

  • A method, computer program and system for analyzing a sample comprising identifying or classifying cells by the ftir spectrum produced by each cell

    JP2018534587A